Cercar

01/05/2025 Strategies for early detection and detailed characterization of oral lesions and head and neck squamous cell carcinoma in Fanconi anemia patients
Beddok, A, Velleuer, E, Fontbrune, FSD, Brakenhoff, RH, Dalle, JH, Dufour, C, Faivre, S, Genet, C, Klijanienko, J, Krieg, C, Leblanc, T, Martinez, P, Latour, RP, Rigolet, A, Saintigny, P, Lyonnet, DS, Soulier, J, Surralles, J, Schramm, M, Thariat, J. Strategies for early detection and detailed characterization of oral lesions and head and neck squamous cell carcinoma in Fanconi anemia patients. CANCER LETTERS. 2025; 617DOI:10.1016/j.canlet.2025.217529. PMID:40054658. IF:10.100(Q1/1D).
01/02/2025 Prognostic significance of mutation type and chromosome fragility in Fanconi anemia
Ramírez, MJ, Pujol, R, Minguillón, J, Bogliolo, M, Persico, I, Cavero, D, de la Cal, A, Río, P, Navarro, S, Casado, JA, Bailador, A, de la Fuente, AS, de Heredia, ML, Almazán, F, Antelo, ML, Argilés, B, Badell, I, Baragaño, M, Beléndez, C, Bermúdez, M, Bernués, M, Buedo, MI, Carrasco, E, Català, A, Costa, D, Cuesta, I, Fernández-Delgado, R, Fernández-Teijeir, A, Figuera, A, García, M, Gondra, A, González, M, Muñiz, SG, Hernández-Rodríguez, I, Ibañez, F, Kelleher, NJ, Lendínez, F, López, M, López-Almaraz, R, Marchante, I, Mendoza, C, Nieto, J, Ojeda, E, Payán-Pernía, S, Peláez, I, de Soto, IP, Portugal, R, Ramos-Arroyo, MA, Regueiro, A, Rodríguez, A, Rosell, J, Saez, R, Sánchez, J, Sánchez, M, Senent, ML, Tapia, M, Trujillo-Quintero, JP, Vagace, JM, Verdú-Amorós, J, Verdugo, V, Vidales, I, Villarreal, J, Díaz-de-Heredia, C, Sevilla, J, Bueren, J, Surralles, J. Prognostic significance of mutation type and chromosome fragility in Fanconi anemia. AMERICAN JOURNAL OF HEMATOLOGY. 2025; 100(2)DOI:10.1002/ajh.27520. PMID:39562502. IF:9.900(Q1/1D).
01/01/2025 Targeting protein-protein interactions in drug discovery: Modulators approved or in clinical trials for cancer treatment
Camps-Fajol, C, Cavero, D, Minguillon, J, Surralles, J. Targeting protein-protein interactions in drug discovery: Modulators approved or in clinical trials for cancer treatment. PHARMACOLOGICAL RESEARCH. 2025; 211DOI:10.1016/j.phrs.2024.107544. PMID:39667542. IF:10.500(Q1/1D).
01/01/2025 A founder variant in the RYR1 gene is associated with hyperCKemia, myalgia and muscle cramps
Segarra-Casas, A, Iruzubieta, P, Kapetanovic, S, Hernández-Laín, A, Jericó, I, Fernández-Torrón, R, Maneiro, M, Marco-Moreno, P, Zelaya-Huerta, MV, Rodríguez-Santiago, B, Calafell, F, Töpf, A, Straub, V, Vallejo-Illarramendi, A, de Munain, AL, Gallano, P, Gonzalez-Quereda, L. A founder variant in the RYR1 gene is associated with hyperCKemia, myalgia and muscle cramps. EUROPEAN JOURNAL OF NEUROLOGY. 2025; 32(1)DOI:10.1111/ene.16471. PMID:39742415. IF:3.900(Q1/3D).